Anti-Vascular Endothelial Growth Factor Therapy for Radiation Retinopathy.
Journal Article (Journal Article;Review)
BACKGROUND AND OBJECTIVE: The purpose of this article is to review the role of anti-vascular endothelial growth factor (VEGF) therapy in treating patients with radiation retinopathy (RR). PATIENTS AND METHODS: RR can be associated with a significant decrease in visual acuity (VA) related to the development of cystoid macular edema, macular ischemia, and proliferative retinopathy leading to neovascular glaucoma. RESULTS: Anti-VEGF therapy is effective at stabilizing VA in around 80% of patients and achieving reductions in central macular thickness when it is administered using a constant algorithm. Furthermore, consistent prophylactic anti-VEGF therapy reduces the risk of development of RR, neovascularization of the iris, and neovascularization glaucoma. CONCLUSION: Future studies are needed to determine the optimal regimen for anti-VEGF therapy according to patient risk factors and likelihood of developing RR. [Ophthalmic Surg Lasers Imaging Retina. 2020;51:S44-S49.].
Full Text
Duke Authors
Cited Authors
- Rayess, N; Mruthyunjaya, P
Published Date
- April 1, 2020
Published In
Volume / Issue
- 51 / 4
Start / End Page
- S44 - S49
PubMed ID
- 32348534
Electronic International Standard Serial Number (EISSN)
- 2325-8179
Digital Object Identifier (DOI)
- 10.3928/23258160-20200401-06
Language
- eng
Conference Location
- United States